FY2026 · ended Mar 31, 2026 · Revenue $1.27M, +161.1% YoY · Filed Jun 15, 2026
Vistagen Therapeutics, Inc. (VTGN) files with the SEC under industry code 2834, Pharmaceutical Preparations. In fiscal 2026, which ended Mar 31, 2026, it reported revenue of $1.3 million and a net loss of $69.7 million. As of Jun 30, 2026 it held $31.7 million in cash and investments and $783,000 in total debt.
Revenue (TTM)
$2.50M
+287.2% vs year-ago TTM
Net income (TTM)
$-67.62M
-21.2% vs year-ago TTM
Operating cash flow (TTM)
$-62.30M
-24.4% vs year-ago TTM
Free cash flow
$-25.81M
+48.6% vs prior year
EPS (TTM)
$-1.66
+7.3% vs year-ago TTM
Dividend per share
None
Shares outstanding
41.03M
+40.7% vs prior year
Net cash
$30.95M
as of Jun 30, 2026
Operating margin
-2785.7%
FY 2027
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- VTGN (Nasdaq)
- Fiscal year ends
- March 31
- Incorporated in
- NV
- Headquarters
- South San Francisco, CA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1411685
- Former names
- Excaliber Enterprises, Ltd. (until Jun 8, 2011)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2026 Mar 31, 2026 |
FY 2025 Mar 31, 2025 |
FY 2024 Mar 31, 2024 |
FY 2023 Mar 31, 2023 |
FY 2022 Mar 31, 2022 |
|---|---|---|---|---|---|
| Revenue | $1.3M | $486,000 | $1.1M | -$227,000 | $1.1M |
| Operating income | -$72.1M | -$56.0M | -$33.0M | -$59.3M | -$47.8M |
| Net income | -$69.7M | -$51.4M | -$29.4M | -$59.2M | -$47.8M |
| Diluted EPS | -$1.83 | -$1.67 | -$1.52 | — | — |
| Operating cash flow | -$66.4M | -$42.1M | -$25.8M | -$49.7M | -$45.3M |
| Free cash flow | — | — | -$25.8M | -$50.2M | -$45.5M |
| Total assets | $48.6M | $84.3M | $123.7M | $21.1M | $74.6M |
| Total liabilities | $13.0M | $14.0M | $9.4M | $9.0M | $9.9M |
| Stockholders' equity | $35.5M | $70.4M | $114.3M | $12.1M | $64.7M |
| Cash and investments | $45.4M | $80.5M | $119.2M | $16.6M | $68.1M |
| Total debt | $948,000 | $1.5M | $2.1M | $2.6M | $3.0M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Exit or restructuring costs, Other events
|
Oct 30, 2026 | Oct 26, 2026 |
| 8-K |
Current report
Officer or director change
|
Oct 9, 2026 | Oct 7, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Sep 25, 2026 | Sep 25, 2026 |
| 8-K |
Current report
Other events
|
Sep 24, 2026 | Sep 24, 2026 |
| 8-K |
Current report
Other events
|
Sep 22, 2026 | Sep 22, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Sep 11, 2026 | Sep 10, 2026 |
All 908 Vistagen Therapeutics, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.